The challenge of the new tuberculosis drugs

Presse Medicale

Volumn 46, Issue 2, 2017, Pages e41-e51

  Tiberi, Simon ^a   Buchanan, Ruaridh ^a   Caminero, José A ^b,c   Centis, Rosella ^d   Arbex, Marcos Abdo ^e   Salazar, Miguel ^f   Potter, Jessica ^a,g   Migliori, Giovanni Battista ^d  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Hospital Nestor Goulart Reis   (Brazil)

^f INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CARBAPENEM; CLAVULANIC ACID; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PHENOTHIAZINE; POSIZOLID; PRETOMANID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; SUTEZOLID; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BONE MARROW SUPPRESSION; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG REPOSITIONING; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; QT PROLONGATION; SHORT SURVEY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; DRUG EFFECTS; EXPERIMENTAL THERAPY; FORECASTING; GENETIC SELECTION; GENETICS; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DISEASE MANAGEMENT; DRUG REPOSITIONING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; SELECTION, GENETIC; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 85013910165     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2017.01.016     Document Type: Short Survey

References (92)

1. [1] World Health Organization, Global tuberculosis report 2016. 2016, World Health Organization, Geneva.
2. [2] World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015 http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_12-en.pdf?ua=1 [accessed on October 2nd, 2016].
3. [3] World Health Organization, WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB 2016. 04. 2016, World Health Organization, Geneva.
4. [4] Combs, D.L., O'Brien, R.J., Geiter, L.J., USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 112 (1990), 397–406.
5. [5] Orenstein, E.W., Basu, S., Shah, N.S., Andrews, J.R., Friedland, G.H., Moll, A.P., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9 (2009), 153–161.
6. [6] Alffenaar, J.W., Akkerman, O.W., Anthony, R., Tiberi, S., Heysell, S., Grobusch, M.P., et al. Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. Expert Rev Anti Infect Ther 15:1 (2017), 11–21.
7. [7] Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H.S., Holtz, T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42 (2013), 156–168.
8. [8] Bastos, M.L., Hussain, H., Weyer, K., Garcia-Garcia, L., Leimane, V., Leung, C.C., et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 59 (2014), 1364–1374.
9. [9] World Health Organization, Treatment of tuberculosis; guidelines. 4th edition, 2014, World Health Organization, WHO/HTM/2009.420. Geneva.
10. [10] Nahid, P., Droman, E., Alipanah, N., Barry, P., Brozek, J., Cattamanchi, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible Tuberculosis. Clin Infect Dis 63 (2016), 853–867.
11. [11] Alffenaar, J.C., Tiberi, S., Verbeeck, R.K., Heysell, S.K., Grobusch, M.P., Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis 64:1 (2017), 105–106 [Epub 2016 Oct 26].
12. [12] Peloquin, C.A., Dorman, S.E., Vernon, A., Battista Migliori, G., Nahid, P., Reply to Alffenaar et al. Clin Infect Dis 64:1 (2017), 105–106 [Epub 2016 Oct 26].
13. [13] Gillespie, S.H., Crook, A.M., McHugh, T.D., Mendel, C.M., Meredith, S.K., Murray, S.R., et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:17 (2014), 1577–1587.
14. [14] Merle, C.S., Fielding, K., Sow, O.B., Gninafon, M., Lo, M.B., Mthiyane, T., et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371:17 (2014), 1588–1598.
15. [15] Jindani, A., Harrison, T.S., Nunn, A.J., Phillips, P.P., Churchyard, G.J., Charalambous, S., et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:17 (2014), 1599–1608.
16. [16] Caminero, J.A., Scardigli, A., Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 46:4 (2015), 887–893, 10.1183/13993003.00432-2015.
17. [17] Rendon, A., Tiberi, S., Scardigli, A., D'Ambrosio, L., Centis, R., Caminero, J.A., et al. Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. J Thorac Dis 8:10 (2016), 2666–2671.
18. [18] Van Deun, A., Maug, A., Salim, A., Das, P., Sarker, M., Daru, P., et al. Short, highly effective, and inexpensive standardised, treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182 (2010), 684–692.
19. [19] Aung, K., Van Deun, A., Declerq, E., Sarker, M.R., Das, P.K., Hossain, M.A., et al. Succesful ‘9- month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 55 consecutive patients. Int J Tuberc Lung Dis 18 (2014), 1180–1187.
20. [20] Piubello, A., Harouna, S., Souleymane, M.B., Boukary, I., Morou, S., Daouda, M., et al. High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuber Lung Dis 18 (2014), 1188–1194.
21. [21] Sotgiu, G., Tiberi, S., D'Ambrosio, L., Centis, R., Zumla, A., Migliori, G.B., WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 387:10037 (2016), 2486–2487, 10.1016/S0140-6736(16)30729-2.
22. [22] Sotgiu, G., Tiberi, S., D'Ambrosio, L., Centis, R., Alffenaar, J.W., Caminero, J.A., Faster for less: the new ‘shorter’ regimen for multidrug-resistant tuberculosis. Eur Respir J, 2016, 10.1183/13993003.01249-2016.
23. [23] Wallis, R.S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G.B., Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 16 (2016), e34–e46.
24. [24] Guglielmetti, L., Le Dû, D., Veziris, N., Caumes, E., Marigot-Outtandy, D., Yazdanpanah, Y., et al. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. Eur Respir J 48:2 (2016), 582–585, 10.1183/13993003.00411-2016 [Epub 2016 Jun 23].
25. [25] Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., Cox, H.S., Holtz, T.H., et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 42:1 (2013), 156–168, 10.1183/09031936.00134712 [Epub 2012 Oct 25].
26. [26] Jawahar, M.S., Banurekha, V.V., Paramasivan, C.N., Rahman, F., Ramachandran, R., Venkatesan, P., et al. Randomized clinical trial of thrice- weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One, 8(7), 2013, e67030.
27. [27] Migliori, G.B., Langendam, M.W., D'Ambrosio, L., Centis, R., Blasi, F., Huitric, E., et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 40:4 (2012), 814–822 [Epub 2012 May 31].
28. [28] Ashtekar, D.R., Costa-Periera, R., Shrinivasan, T., Iyyer, R., Vishvanathan, N., Rittel, W., Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 14 (1991), 465–471.
29. [29] Lee, M., Lee, J., Carroll, M.W., Choi, H., Min, S., Song, T., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367 (2012), 1508–1518.
30. [30] Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.W., Anger, H.A., Caminero, J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 40 (2012), 1430–1442.
31. [31] Sotgiu, G., Pontali, E., Migliori, G.B., Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 45:1 (2015), 25–29, 10.1183/09031936.00145014.
32. [32] Van Deun, A., Salim, M.A., Das, A.P., Bastian, I., Portaels, F., Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 8 (2004), 560–567.
33. [33] Geerligs, W.A., van Altena, R., de Lange, W.C.M., van Soolingen, D., van der Werf, T.S., Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 4 (2000), 758–764.
34. [34] Tang, S., Yao, L., Hao, X., Liu, Y., Zeng, L., Liu, G., et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 60 (2015), 1361–1367.
35. [35] Aung, K.J., Van Deun, A., Declercq, E., Sarker, M.R., Das, P.K., Hossain, M.A., et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 18:10 (2014), 1180–1187, 10.5588/ijtld.14.0100.
36. [36] Chambers, H.F., Turner, J., Schecter, G.F., Kawamura, M., Hopewell, P.C., Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 49 (2005), 2816–2821.
37. [37] Hugonnet, J.E., Tremblay, L.W., Boshoff, H.I., Barry, C.E. 3rd., Blanchard, J.S., Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323 (2009), 1215–1218.
38. [38] De Lorenzo, S., Alffenaar, J.W., Sotgiu, G., Centis, R., D'Ambrosio, L., Tiberi, S., et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 41 (2013), 1386–1392.
39. [39] Tadolini, M., Garcia-Prats, A.J., D'Ambrosio, L., Hewison, C., Centis, R., Schaaf, H.S., et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 48:3 (2016), 938–943, 10.1183/13993003.00705-2016.
40. [40] Tiberi, S., Payen, M.C., Sotgiu, G., D'Ambrosio, L., Alarcon Guizado, V., Alffenaar, J.W., et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 47:4 (2016), 1235–1243, 10.1183/13993003.02146-2015.
41. [41] Tiberi, S., Sotgiu, G., D'Ambrosio, L., Centis, R., Arbex, M.A., Alarcon Arrascue, E., et al. Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 62:9 (2016), 1188–1190, 10.1093/cid/ciw088.
42. [42] Sotgiu, G., D'Ambrosio, L., Centis, R., Tiberi, S., Esposito, S., Dore, S., et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci, 17(3), 2016, 373, 10.3390/ijms17030373.
43. [43] Diacon, A.H., van der Merwe, L., Barnard, M., von Groote-Bidlingmaier, F., Lange, C., García-Basteiro, A.L., et al. Β-Lactams against Tuberculosis – new trick for an old dog?. N Engl J Med 375:4 (2016), 393–394, 10.1056/NEJMc1513236.
44. [44] Tiberi, S., D'Ambrosio, L., De Lorenzo, S., Viggiani, P., Centis, R., Sotgiu, G., et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 47:1 (2016), 333–336, 10.1183/13993003.01278-2015.
45. [45] Anglaret, X., Chêne, G., Attia, A., Toure, S., Lafont, S., Combe, P., et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 353 (1999), 1463–1468.
46. [46] Walker, A.S., Ford, D., Gilks, C.F., Munderi, P., Ssali, F., Reid, A., et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375 (2010), 1278–1286.
47. [47] Hoffmann, C.J., Chaisson, R.E., Martinson, N.A., Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS One, 9, 2014, e83750.
48. [48] Alsaad, N., Wilffert, B., van Altena, R., de Lange, W.C., van der Werf, T.S., Kosterink, J.G., et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 43:3 (2014), 884–897, 10.1183/09031936.00113713.
49. [49] Krieger, D., Vesenbeckh, S., Schönfeld, N., Bettermann, G., Bauer, T.T., Rüssmann, H., et al. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J 46:5 (2015), 1503–1505, 10.1183/13993003.00321-2015.
50. [50] Caminero JA1, Sotgiu, G., Zumla, A., Migliori, G.B., Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10:9 (2010), 621–629, 10.1016/S1473-3099(10)70139-0.
51. [51] Grosset, J.H., Singer, T.G., Bishai, W.R., Grosset, J.H., New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 16:8 (2012), 1005–1014, 10.5588/ijtld.12.0277.
52. [52] Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H.W.H., Neefs, J.-M., Winkler, H., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:5707 (2005), 223–227.
53. [53] Pontali, E., Sotgiu, G., D'Ambrosio, L., Centis, R., Migliori, G.B., Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J 47:2 (2016), 394–402, 10.1183/13993003.01891-2015.
54. [54] Tiberi, S., De Lorenzo, S., Centis, R., Viggiani, P., D'Ambrosio, L., Migliori, G.B., Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 43:1 (2014), 289–292, 10.1183/09031936.00122313.
55. [55] van Halsema, C., Humphreys, S., Bonington, A., Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 43:1 (2014), 292–294, 10.1183/09031936.00128613.
56. [56] Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., et al. The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. N Engl J Med 360 (2009), 2397–2405.
57. [57] Diacon, A.H., Pym, A., Grobusch, M.P., de los Rios, J.M., Gotuzzo, E., Vasilyeva, I., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371 (2014), 723–732.
58. [58] Centers for Disease Control and Prevention, Provisional CDC Guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 62 (2013), 1–12.
59. [59] Guglielmetti, L., Jaspard, M., Le Dû, D., Lachâtre, M., Marigot-Outtandy, D., Bernard, C., et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. ERJ, 2016, 10.1183/13993003.01799-2016 [Epub ahead of print. PMID: 28182570. pii: 1601799].
60. [60] Veziris, N., Bernard, C., Guglielmetti, L., Le Du, D., Marigot-Outtandy, D., Jaspard, M., et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons not to repeat past errors. Eur Respir J, 2016, 10.1183/13993003.01719-2016 [Epub ahead of print pii: 1601719].
61. [61] Lachâtre, M., Rioux, C., Le Dû, D., Fréchet-Jachym, M., Veziris, N., Bouvet, E., et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis, 16(3), 2016, 294, 10.1016/S1473-3099(16)00047-5.
62. [62] Tadolini, M., Lingtsang, R.D., Tiberi, S., Enwerem, M., D'Ambrosio, L., Sadutshang, T.D., et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 48:3 (2016), 935–938, 10.1183/13993003.00637-2016.
63. [63] Wallis, R.S., Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 48:5 (2016), 1526–1527, 10.1183/13993003.01207-2016.
64. [64] Tadolini, M., Lingtsang, R.D., Tiberi, S., Enwerem, M., D'Ambrosio, L., Sadutshang, T.D., et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 48:5 (2016), 1527–1529, 10.1183/13993003.01552-2016.
65. [65] Lewis, J.M., Hine, P., Walker, J., Khoo, S.H., Taegtmeyer, M., Squire, S.B., et al. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Eur Respir J 47:5 (2016), 1581–1584, 10.1183/13993003.01980-2015 [Epub 2016 Feb 25].
66. [66] Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Derivative with promising action against tuberculosis in vitro and in mice. PLOS Med, 3(11), 2006.
67. [67] Gler, M.T., Skripconoka, V., Sanchez-Garavito, E., Xiao, H., Cabrera-Rivero, J.L., Vargas-Vasquez, D.E., et al. Delamanid for Multidrug-resistant pulmonary tuberculosis. N Engl J Med 366 (2012), 2151–2160.
68. [68] Skripconoka, V., Danilovits, M., Pehme, L., Tomson, T., Skenders, G., Kummik, T., et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41:6 (2013), 1393–1400.
69. [69] Esposito, S., D'Ambrosio, L., Tadolini, M., Schaaf, H.S., Caminero Luna, J., Marais, B., et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 44:3 (2014), 811–815, 10.1183/09031936.00060414.
70. [70] World Health Organization, The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidance. 2016, World Health Organization, Geneva 6, WHO interim policy recommendations for the use of delamanid in children and adolescents. Available from: https://www.ncbi.nlm.nih.gov/books/NBK396134/.
71. [71] Diacon, A.H., Dawson, R., Bois, J., Narunsky, K., Venter, A., Donald, P.R., et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 56:6 (2012), 3027–3031, 10.1128/AAC.06125-11 [PMID: 22430968].
72. [72] Dawson, R., Diacon, A.H., Everitt, D., Niekerk, C., Donald Van, P.R., et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385:9979 (2015), 1738–1747.
73. [73] WHO, WHO Factsheet: the Shorter MDR-TB regimen. 2016 Available from: http://www.who.int/tb/Short_MDR_regimen_factsheet.pdfhttp://www.who.int/tb/Short_MDR_regimen_factsheet.pdf.
74. [74] Moodley, R., Godec, T.R., STREAM Trial Team, Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. 2016, 29–35 Available from: http://dx.doi.org/10.1183/16000617.0080-2015http://dx.doi.org/10.1183/16000617.0080-2015.
75. [75] Clinical Trials Gov NCT02333799. https://clinicaltrials.gov [accessed 23rd October 2016].
76. [76] Conradie, F., Diacon, A., Mendel, C., Everitt, D., Van Niekerk, C., Howell, P., et al. Interim results of nix-TB clinical study of pretomanid, bedaquiline and linezolid for treatment of XDR and treatment intolerant/failed MDR-TB. OA-3117 presented at the 47th Union World Conference on Lung Health, Liverpool, UK: 26 October–29 October 2016, 2016.
77. [77] Wolfson, L.J., Walker, A., Hettle, R., Lu, X., Kambili, C., Murungi, A., et al. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. 2015, 1–20.
78. [78] Hoagland, D.T., Liu, J., Lee, R.B., Lee, R.E., New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev A 102 (2016), 55–72, 10.1016/j.addr.2016.04.026 [Epub 2016 May 2].
79. [79] Bloemberg, G.V., Keller, P.M., Stucki, D., Trauner, A., Borrell, S., Latshang, T., et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 370:20 (2015), 1986–1988.
80. [80] Daniels, M., Hill, A.B., Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials. Br Med J 1 (1952), 1162–1168.
81. [81] Crofton, J., The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line. J R Soc Med 99 (2006), 531–534, 10.1258/jrsm.99.10.531.
82. [82] Podewils, L.J., Gler, M.T., Quelapio, M.I., Chen, M.P., Patterns of treatment interruption among patients with multidrug-resistant TB (MDR-TB) and association with interim and final treatment outcomes. PLoS One, 8(7), 2013, e70064, 10.1371/journal.pone.0070064. Print 2013.
83. [83] Gupta, R., Joel Brenner, M.G., Henry, C.L., et al. Procurement of second-line anti-tuberculosis drugs for dots-plus pilot projects WHO Working Group on DOTS-Plus for MDR-TB. 1999 WHO/CDS/TB/2000.276. Available on http://apps.who.int/iris/bitstream/10665/66166/1/WHO_CDS_TB_2000.276.pdf.
84. [84] Kuaban, C., Noeske, J., Reider, H.L., Aït-Khaled, N., Abena Foe, J.L., Trébucq, A., High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 19 (2015), 517–524 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=25868018.
85. [85] Piubello, A., Harouna, S.H., Souleymane, M.B., Boukary, I., Morou, S., Daouda, M., et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 18 (2014), 1188–1194, 10.5588/ijtld.13.0075.
86. [86] Nunn, A.J., Rusen, I.D., Van Deun, A., Torrea, G., Phillips, P.P., Chiang, C.Y., et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 15, 2014, 353, 10.1186/1745-6215-15-353.
87. [87] Ittner, K.P., Gatifloxacin and dysglycemia in older adults. N Engl J Med 354 (2006), 2725–2726, 10.1056/NEJMc066207.
88. [88] Chiang, C.-Y., Van Deun, A., Rieder, H.L., Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 20 (2016), 1143–1147, 10.5588/ijtld.15.0884.
89. [89] Mitnick, C.D., Rusen, I., Bain, L.J., Horsburgh, C.R., Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting. BMC Proc, 9, 2015, S1, 10.1186/1753-6561-9-S8-S1.
90. [90] Moore, D.A.J., What can we offer to 3 million MDRTB household contacts in 2016?. BMC Med, 14, 2016, 64, 10.1186/s12916-016-0610-x.
91. [91] Pollett, S., Banner, P., O'Sullivan, M.V.N., Ralph, A.P., Epidemiology, diagnosis and management of extra-pulmonary tuberculosis in a low-prevalence country: a four year retrospective study in an Australian tertiary infectious diseases unit. PLoS One, 11, 2016, e0149372, 10.1371/journal.pone.0149372.
92. [92] PHE, Tuberculosis in England 2015 Report. 2015, Public Heal Engl [Version 1].